Jonathan Cohen discusses hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society

Jonathan Cohen, Director of Clinical Research at Sharett Institute of Oncology of Hadassah Medical Center, shared on LinkedIn:

“I had the opportunity to discuss various topics in hepatocellular carcinoma at the annual meeting of the Israeli Oncology Society (ISCORT).

Some points of discussion:

• Should all HCC patients undergo biopsies?
  – This will probably become SOC soon with ADC’s and other biomarker-driven therapies; but not yet.
• When should systemic therapies be introduced?
  – Adjuvant data is not ripe, but I would strongly consider when loco-regional disease recurs. Survival data will be crucial.
  – Neoadjuvant treatment makes sense. Awaiting data.
  – Downstaging with ICI before liver transplant – some ongoing single institution studies. Risk of rejection? Loss of systemic protection due to immune-suppression? vs. potential for cure?
• How should increased LFT’s be handled in HCC patients receiving ICI?
  – Don’t rush to label as irAE.
• What’s going on in the clinical research arena for HCC?
  – ADC’s
  – Immune-cell engagers
  – Novel combinations
  – Personalized neoantigen vaccine.”

View additional information.
Source: Jonathan Cohen/LinkedIn